SOPHiA GENETICS (NASDAQ:SOPH) reported a record-breaking performance for 2025, driven by a surge in demand for its AI-powered genomic analysis, as the company prepares for a major leadership transition and moves closer to profitability.
The Swiss-American healthcare technology firm announced preliminary fourth-quarter revenue of at least $21 million, an approximately 20% jump year-over-year.
For the full year 2025, revenue reached $77 million, marking an 18% increase from the prior year.
The growth was underpinned by a massive expansion in platform activity; the company performed a record 391,000 analyses on its SOPHiA DDM™ platform in 2025, with more than 105,000 conducted in the final three months alone.
Alongside the financial results, SOPHiA unveiled a long-term succession plan.
Ross Muken, the company’s current President and former CFO, will be promoted to Chief Executive Officer on July 1, 2026.
Co-founder and current CEO Jurgi Camblong will transition to Executive Chairman, focusing on the company’s long-term strategic vision and board governance.
Looking ahead to 2026, the company expects revenue growth to accelerate further, guiding for $92 million to $94 million—representing a 20% to 22% increase.
Crucially, the company is narrowing its losses as it scales, projecting an adjusted EBITDA loss of $29 million to $32 million for the coming year.
Management also reaffirmed its commitment to reaching adjusted EBITDA breakeven by the end of 2026, a milestone that has been a key focus for investors as the company seeks to prove the scalability of its AI-driven precision medicine model.